Heterologous SARS-CoV-2 Booster Vaccinations - Preliminary Report.
Robert L AtmarKirsten E LykeMeagan E DemingLisa A JacksonAngela R BrancheHana M El SahlyChristina A RostadJudith M MartinChristine JohnstonRichard E RuppMark J MulliganRebecca C BradyRobert W FrenckMartín BäckerAngelica C KottkampTara M BabuKumaravel RajakumarSrilatha EdupugantiDavid DobryzynskiChristine M PosavadJanet I ArcherSonja CrandonSeema U NayakDaniel SzydloJillian ZemanekClara P Dominguez IslasElizabeth R BrownMehul S SutharM Juliana McElrathAdrian B McDermottSarah E O'ConnellDavid C MontefioriAmanda EatonKathleen M NeuzilDavid S StephensPaul C RobertsJohn H Beigelnull nullPublished in: medRxiv : the preprint server for health sciences (2021)
Homologous and heterologous booster vaccinations were well-tolerated and immunogenic in adults who completed a primary Covid-19 vaccine regimen at least 12 weeks earlier. (Funded by National Institute of Allergy and Infectious Diseases; Clinical Trials.gov number, NCT04889209 ).